Core Viewpoint - The stock of LaiKai Pharmaceutical (02105) has seen a significant increase of over 5%, currently trading at 12.82 HKD, following the publication of promising clinical trial results for its drug LAE002 in the treatment of advanced breast cancer [1] Group 1: Clinical Trial Results - The international scientific journal Nature Communications published a study led by Professor Xu Binghe, indicating that the combination treatment of Afuresertib and Fulvestrant shows encouraging anti-tumor activity and good safety profiles in patients with HR+ HER2- advanced breast cancer [1] - The ongoing Phase III clinical trial AFFIRM-205 for LAE002, which is an AKT inhibitor developed by LaiKai Pharmaceutical, is progressing smoothly, with completion of patient enrollment expected by December 2025 [1] Group 2: Regulatory and Commercialization Plans - LaiKai Pharmaceutical plans to submit a new drug application to the China National Medical Products Administration in the middle of this year, aiming to release top-line data from the Phase III trial in the first half of this year [1] - In November 2025, LaiKai Pharmaceutical signed an exclusive licensing agreement with Qilu Pharmaceutical for the commercialization of LAE002 in China [1]
来凯医药午前涨超5% LAE002临床研究成果登上《自然-通讯》杂志